The NRG-HN004 phase 2/3 trial was stopped after a planned interim futility analysis suggested that PD-L1 inhibition with durvalumab and radiotherapy was unlikely to improve outcomes over standard cetuximab with radiotherapy for patients with HNSCC and a contraindication to cisplatin. Here, CD274 is linked to head and neck squamous cell carcinoma.